Wednesday, September 27, 2023
June 02 - 06, 2017; Chicago, Illinois
ASCO
Pembrolizumab Flat Dosing Wastes Nearly $1 Billion Annually
ASCO
Neoadjuvant Pembrolizumab Promising in Head and Neck Cancer
ASCO
Triple Therapy Potent Approach in Aggressive Skin Cancer
ASCO
Possible Role for Immunotherapy in Early-Stage Breast Cancer
ASCO
Lenvatinib May Be New First-Line Option in Advanced HCC
ASCO
Immunotherapy for Melanoma Brain Mets: 'Practice Changing'
ASCO
In Lymphoma, Best Partner With Rituximab Still in Question
ASCO
Lots of Unneeded Interventions in Early Breast Cancer
ASCO
No Need for Lymphadenectomy in Advanced Ovarian Cancer
ASCO
Is Big Study at ASCO Really a 'Tipping Point'?
ASCO
Alectinib: New Standard in ALK-Positive Lung Cancer
ASCO
Liquid Biopsies: Too Soon for Cancer Detection
ASCO
Up-front Abiraterone in Prostate Cancer: Which Patients?
ASCO
SUNSHINE: Vitamin D Slows Colon Cancer Progression
ASCO
NCI-Funded Trials Have Extended Lives of US Patients With Cancer
ASCO
Dacomitinib: Potential New EGFR Inhibitor for First-Line NSCLC
ASCO
Oncologists Need Help to Discuss Costs With Patients
ASCO
Likely New Option for Mesothelioma: Immunotherapy
ASCO
Re-excision Rates Plummet After Negative Margin Guideline
ASCO
Is APHINITY the End of the Line for Trastuzumab Add-ons?
ASCO
Finding Patients for Targeted Therapies in Routine Practice
ASCO
'Striking Results' in All Cancer Types: Larotrectinib
ASCO
Less Is More: Patients With Colon Cancer Get a Chemo Break
ASCO
If This Were a Drug, the Price Would Be $100,000
ASCO
Olaparib: New Standard for BRCA-Mutated Breast Cancer?
ASCO
Abiraterone: Now Upfront for Advanced Prostate Cancer?
ASCO
Yes, a Pregnancy After Breast Cancer Is Safe
ASCO
One RT Dose Enough for Metastatic Spinal Cord Compression
ASCO
'Not Part of Routine Cancer Care,' But Should Be
ASCO
Hypogonadism Common in Testicular Cancer Survivors
ASCO
What's Hot at ASCO 2017?
ASCO
Reducing Risk After Cancer: Healthy Lifestyle (and Tree Nuts)
ASCO
Could Gefitinib Replace Adjuvant Chemo in NSCLC?
ASCO
Large Study Shows Reduced Oral HPV Infections With Vaccine
ASCO
Biliary Tract Cancer Data 'Will Change Practice Overnight'
Medscape Oncology©
WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
'Moving the Needle' in Oncology Workforce Diversity
Beyond APHINITY: What Now After Pivotal Breast Cancer Trial?
Why Do Physicians Overtreat Elderly Breast Cancer Patients?
Combination Therapies: A Tipping Point for Cancer Drug Costs?
Immunotherapy for Lung Cancers: First-Line and Beyond
'Dealing With the Hype': Communicating and the Art of Oncology
Ipilimumab Plus Nivolumab for Melanoma Patients With Brain Metastases
New Data Provide Even More Support for Exercise During Cancer
Combo Data Creates New Choices in Metastatic Prostate Cancer
New Data Change Metastatic Prostate Cancer Treatment Paradigm
Oncologists Still Avoid Discussing Cost of Care
New Data Address Critical Surgical Questions in Ovarian Cancer
Essential Cancer Updates for Primary Care Physicians
In Immunotherapy, Approved Biomarkers Pose Many Problems
Alok Khorana: How ASCO 2017 Changed My GI Oncology Practice
Peter Bach: Cancer Drugs Not Working Hard Enough for the Money
Adjuvant TKI Therapy for Early-Stage
EGFR Mutation-Positive NSCLC
Potential ASCO Practice-Changers in HER2+ Breast Cancer
Cultivating Resiliency and Combating Burnout in Oncology
New CDK4/6i Data Move Metastatic Breast Cancer Field Forward
Joseph Mikhael: ASCO 2017 Takeaways in Myeloma
Managing the Unique Challenges of Opioids in Cancer Care
'Tumor-Agnostic' Approvals a Paradigm Shift, With Many Questions
Will pCR and Pembro Redefine Breast Cancer Treatment?
At ASCO, a Guide to Relieve Mounting Practice Pressures
Best of the 2017 ASCO Live Blog
OlympiAD: Olaparib Captures Gold for BRCA-Mutated Breast Cancer Patients
Good IDEA: Drop Adjuvant Chemo From 6 to 3 Months in CRC
Landmark Trial: Patient-Generated Data Improve Cancer Survival
First Look at New Data on CDK 4/6 Inhibitors in Metastatic Breast Cancer
Len Saltz on Hype vs Hope, Drug Costs, and ASCO 2017
Top Melanoma Studies to Be Presented at ASCO
Will Adjuvant Oxaliplatin Data Change Practice in Colon Cancer?
Prostate Cancer Preview: ASCO 2017 Data Likely to Change Practice
Two 'P' Words Top List of Hot Topics in Breast Cancer
Advances in Gynecologic Cancer: ASCO 2017
What's New for Lung Cancer? Stay Tuned for ASCO 2017
